GTHX(Delisted)
G1 TherapeuticsยทNASDAQ
--
--(--)
GTHX Profile
G1 Therapeutics, Inc.
A commercial-stage biopharmaceutical company that developing novel small molecule therapeutics for the treatment of cancer
700 Park Offices Drive, Suite 200, Research Triangle Park, NC 27709
--
G1 Therapeutics, Inc., was incorporated under the laws of the State of Delaware on May 19, 2008 under the name "G-Zero Therapeutics, Inc.". In September 2012, they changed their name to "G1 Therapeutics, Inc.". The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapies for the treatment of cancer patients. COSELA (trilaciclib), the first product approved by the US Food and Drug Administration, is the first and only therapy proven to actively help protect bone marrow from damage from chemotherapy (bone marrow protection) and the first innovation in managing bone marrow protection in decades. In July 2022, COSELA (Trasilib Hydrochloride for Injection) was conditionally approved by the National Medical Products Administration to be marketed in China.
